Alliance Pharma PLC has released its block listing six-monthly return, covering the period from 28 June 2023 to 31 December 2023. The return details the number of securities originally admitted at the date of admission, the balance of unallotted securities under schemes from the previous return, and the amount by which the block schemes have been increased since the date of the last return. It also includes the number of securities issued/allotted under schemes during the period and the balance under schemes not yet issued/allotted at the end of the period.
The company's contact information is provided, including the name of the Company Secretary and the telephone number for further inquiries. Additionally, contact details for Alliance Pharma plc and its Head of Investor Relations are listed, along with the contact information for Buchanan, Deutsche Numis, and Investec Bank plc.
Alliance Pharma plc is described as a growing consumer healthcare company with the purpose of empowering people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company's strategy involves delivering organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. It also mentions the possibility of enhancing organic growth through selective, complementary acquisitions.
This information was supplied by Euroland.com and includes a link to their Privacy Policy.
This summary provides an overview of Alliance Pharma PLC's block listing six-monthly return, contact information, and a brief description of the company's purpose and growth strategy.